A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dexcom Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 955,500 shares of DXCM stock, worth $72.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
955,500
Previous 540,600 76.75%
Holding current value
$72.5 Million
Previous $61.3 Million 4.48%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$64.0 - $116.06 $32.4 Million - $58.7 Million
505,959 Added 69.51%
1,233,844 $82.7 Million
Q2 2024

Aug 14, 2024

BUY
$110.31 - $140.45 $3.92 Million - $4.99 Million
35,503 Added 5.13%
727,885 $82.5 Million
Q1 2024

May 15, 2024

SELL
$114.22 - $140.1 $192 Million - $236 Million
-1,683,378 Reduced 70.86%
692,382 $96 Million
Q4 2023

Feb 14, 2024

BUY
$75.49 - $124.16 $108 Million - $178 Million
1,432,110 Added 151.76%
2,375,760 $295 Million
Q3 2023

Nov 14, 2023

BUY
$86.06 - $137.93 $59 Million - $94.6 Million
685,606 Added 265.69%
943,650 $88 Million
Q2 2023

Aug 14, 2023

SELL
$112.47 - $130.98 $425 Million - $495 Million
-3,780,330 Reduced 93.61%
258,044 $33.2 Million
Q1 2023

May 15, 2023

BUY
$104.0 - $122.92 $188 Million - $222 Million
1,805,530 Added 80.86%
4,038,374 $469 Million
Q4 2022

Feb 14, 2023

BUY
$84.98 - $122.67 $135 Million - $194 Million
1,583,317 Added 243.76%
2,232,844 $253 Million
Q3 2022

Nov 14, 2022

SELL
$76.35 - $94.18 $185 Million - $228 Million
-2,421,347 Reduced 78.85%
649,527 $52.3 Million
Q2 2022

Aug 15, 2022

BUY
$67.99 - $132.89 $188 Million - $366 Million
2,757,773 Added 880.79%
3,070,874 $229 Million
Q1 2022

May 16, 2022

BUY
$94.08 - $130.2 $15.4 Million - $21.4 Million
164,176 Added 110.24%
313,101 $160 Million
Q4 2021

Feb 14, 2022

SELL
$129.87 - $162.82 $4.54 Million - $5.69 Million
-34,923 Reduced 19.0%
148,925 $20 Million
Q3 2021

Nov 15, 2021

BUY
$106.71 - $143.18 $19.2 Million - $25.7 Million
179,527 Added 4154.76%
183,848 $101 Million
Q2 2021

Aug 16, 2021

SELL
$80.99 - $107.93 $9.93 Million - $13.2 Million
-122,557 Reduced 96.59%
4,321 $461,000
Q1 2021

May 17, 2021

BUY
$84.79 - $104.74 $10.2 Million - $12.6 Million
120,749 Added 1970.13%
126,878 $45.6 Million
Q4 2020

Feb 16, 2021

SELL
$78.0 - $104.5 $10.4 Million - $14 Million
-133,890 Reduced 95.62%
6,129 $2.27 Million
Q3 2020

Nov 16, 2020

SELL
$95.51 - $112.95 $3.74 Million - $4.42 Million
-39,140 Reduced 21.85%
140,019 $57.7 Million
Q2 2020

Aug 14, 2020

SELL
$62.68 - $105.34 $9.87 Million - $16.6 Million
-157,393 Reduced 46.77%
179,159 $72.6 Million
Q1 2020

May 15, 2020

SELL
$47.79 - $75.63 $4.66 Million - $7.38 Million
-97,538 Reduced 22.47%
336,552 $90.6 Million
Q4 2019

Feb 14, 2020

BUY
$36.62 - $57.29 $11.7 Million - $18.3 Million
319,006 Added 277.19%
434,090 $95 Million
Q3 2019

Nov 14, 2019

SELL
$35.53 - $43.8 $12.7 Million - $15.6 Million
-356,217 Reduced 75.58%
115,084 $4.29 Million
Q2 2019

Aug 14, 2019

BUY
$27.84 - $38.92 $5.61 Million - $7.85 Million
201,638 Added 74.77%
471,301 $70.6 Million
Q1 2019

May 15, 2019

SELL
$28.07 - $38.18 $561,596 - $763,867
-20,007 Reduced 6.91%
269,663 $0
Q4 2018

Feb 14, 2019

SELL
$26.99 - $37.37 $18.6 Million - $25.7 Million
-688,671 Reduced 70.39%
289,670 $8.68 Million
Q3 2018

Nov 13, 2018

BUY
$23.35 - $36.72 $7.54 Million - $11.9 Million
323,017 Added 49.29%
978,341 $0
Q2 2018

Aug 10, 2018

BUY
$17.54 - $25.22 $8.37 Million - $12 Million
477,447 Added 268.41%
655,324 $0
Q1 2018

May 11, 2018

BUY
$13.06 - $18.54 $1.54 Million - $2.19 Million
117,890 Added 196.53%
177,877 $13.2 Million
Q4 2017

Feb 09, 2018

SELL
$11.12 - $15.38 $1.48 Million - $2.04 Million
-132,661 Reduced 68.86%
59,987 $3.44 Million
Q3 2017

Nov 09, 2017

BUY
$11.36 - $18.98 $2.19 Million - $3.66 Million
192,648
192,648 $9.43 Million

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $29.3B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.